Background: The World Health Organization (WHO) plays a critical role in global health governance, but its popular legitimacy, a measure of public trust and support, has been contested, particularly during crises such as the COVID-19 pandemic. While legitimacy is widely studied through normative and elite-focused approaches, empirical assessments using public discourse remain limited. Social media platforms like X (formerly Twitter) offer real-time data for evaluating public sentiment toward the WHO. Objective: This study aims to assess the evolution of the WHO’s popular legitimacy from 2008 to 2021 by analyzing public engagement metrics on X, with a particular focus on changes during the COVID-19 pandemic. Methods: We analyzed 46,667 tweets from the WHO using computational methods, including the retweet-to-reply ratio, sentiment analysis, and longitudinal trend evaluation. Metrics such as likes, retweets, and replies were examined to quantify public sentiment, with the retweet-to-reply ratio serving as a key indicator of controversy and support levels. Results: The WHO’s popular legitimacy was stable from 2008 to 2019 but declined significantly during the COVID-19 pandemic, reflecting heightened public scrutiny and criticism. Engagement metrics revealed increased replies relative to retweets during this period, indicating greater controversy in public discourse. Conclusions: This study demonstrates the feasibility of using social media metrics to measure international organization (IO) legitimacy over time. The findings highlight the impact of global crises on public trust and provide a replicable framework for assessing the legitimacy of other IOs. Social media engagement offers valuable insights for IOs to adapt communication strategies and maintain public trust during crises. Trial Registration:
Randomized controlled trial to evaluate an app-based multimodal digital intervention for people with type 2 diabetes in comparison to a placebo app
IntroductionThis multi-center, parallel-group randomized controlled trial evaluated the app-based intervention mebix, developed by Vision2b GmbH in Germany, for people with type 2 diabetes compared to


